Sedative/hypnotic dependence: patient stabilization, tolerance testing, and withdrawal.
Physical dependence to sedative/hypnotic drugs is not an uncommon clinical problem. The withdrawal syndrome is analogous to alcohol withdrawal, except the duration of the syndrome occurs over a longer period of time with the symptoms being less intense than generally encountered with alcohol. The potential for withdrawal reactions is probably greater for the shorter-acting agents than the longer-acting drugs. Potentially dependent sedative/hypnotic users require stabilization of their symptoms initially, followed by tolerance testing. If tolerant, the patients should be withdrawn using either a long-acting sedative/hypnotic (e.g., diazepam) or phenobarbital. Compared to other benzodiazepines and barbiturates, diazepam appears to be the drug of choice for treating dependent patients. Diazepam is rapidly absorbed and distributed to the brain and therefore useful for stabilization and tolerance testing. It is metabolized on chronic administration to a long-acting metabolite, desmethyldiazepam, which makes the drug ideal for a tapered withdrawal schedule.
D014151:Anti-Anxiety Agents; D001463:Barbiturates; D003975:Diazepam; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance; D006801:Humans; D006993:Hypnotics and Sedatives / Q000378:metabolism; D010634:Phenobarbital; D011433:Propranolol; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000378:metabolism / Q000628:therapy*; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000628:therapy*; D013997:Time Factors
D014151:Anti-Anxiety Agents; D001463:Barbiturates; D006993:Hypnotics and Sedatives; D011433:Propranolol; D003975:Diazepam; D010634:Phenobarbital